This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Effect of Vitamin D Supplementation on Disease Activity Markers in Systemic Lupus Erythematosus (SLE)

This study has been completed.
Information provided by (Responsible Party):
Anna Abou-Raya, Faculty of Medicine, University of Alexandria Identifier:
First received: August 18, 2011
Last updated: August 27, 2011
Last verified: August 2011

Systemic lupus erythematosus (SLE) is a chronic multi-system inflammatory autoimmune disease. Vitamin D has potent immunomodulatory properties that have promoted its potential use in the treatment of autoimmune conditions, including SLE. We assessed vitamin D status in SLE patients and determined alterations in inflammatory, hemostatic markers as well as disease activity before and after vitamin D supplementation.

248 SLE patients were enrolled in this randomized placebo-controlled study. Patients were randomized 2:1 to receive either oral cholecalciferol 2000 IU/day or placebo for 12 months. Outcome measures included assessment of alterations in levels of IL-1, IL-6, IL-18, TNF-alpha, Anti-dsDNA, ANA, fibrinogen and von Willebrand Factor (vWF) before and after 12 months supplementation. Disease activity was measured by the SLEDAI. Vitamin D levels were measured by Liaison immunoassay; (normal 30-100ng/ml). Serum levels between 10-30 ng/ml were classified as vitamin D insufficiency, and levels < 10 ng/ml as vitamin D deficiency.The mean 25(OH) D level at baseline was 19.8 ng/ml in patients compared to 28.7 ng/ml in controls.

Condition Intervention
Systemic Lupus Erythematosus Drug: vitamin D 25(OH)D Other: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Anna Abou-Raya, Faculty of Medicine, University of Alexandria:

Primary Outcome Measures:
  • Decrease in SLE disease activity [ Time Frame: 12 months ]

Enrollment: 248
Study Start Date: April 2010
Study Completion Date: May 2011
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Vitamin D Drug: vitamin D 25(OH)D
2000IU/day for 12 months
Placebo Comparator: Placebo Other: Placebo
2000IU/day of vitamin D will be compared to similar looking tablets of placebo for 12 months


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Premenopausal women and males of the same body mass index and ethnicity

Exclusion Criteria:

Patients with:

  • other inflammatory disorders,
  • hepatic disease
  • renal disease
  • malignant disease.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01425775

Faculty of Medicine, University of Alexandria
Alexandria, Egypt, 00203
Sponsors and Collaborators
Faculty of Medicine, University of Alexandria
Principal Investigator: Anna Abou-Raya, MD Faculty of Medicine, University of Alexandria
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Anna Abou-Raya, Professor of Rheumatology, Faculty of Medicine, University of Alexandria Identifier: NCT01425775     History of Changes
Other Study ID Numbers: alexmed116618166
Study First Received: August 18, 2011
Last Updated: August 27, 2011

Keywords provided by Anna Abou-Raya, Faculty of Medicine, University of Alexandria:
disease activity markers
vitamin D

Additional relevant MeSH terms:
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Vitamin D
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents processed this record on September 19, 2017